NFE2L1 and familial pancreatic carcinoma: Therefore, we performed an evaluation of the effects of T3, TOS, and T3E on NFE2L1 and sensitivity to bortezomib in the lung adenocarcinoma cell line, A549, and the pancreatic cancer cell line, PANC1.